SCHEMBL4787556

SCHEMBL4787556

O=C1CCCc2nc(-c3nc(-c4ccccc4)cn3-c3ccccc3)ccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.44
HPGD P15428 4/20 0.43
KDM4E B2RXH2 4/20 0.43
MAPT P10636 4/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 6/20 0.39
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 2/20 0.39
PTGS2 P35354 1/20 0.38
KMT2A Q03164 3/20 0.37
TSHR P16473 1/20 0.37
MEN1 O00255 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MITF O75030 1/20 0.37
PKM P14618 1/20 0.37
HSD17B10 Q99714 1/20 0.36
ELANE P08246 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30558432 0.82 GRM5 (0.57) GRM5HPGDKDM4EMAPTUSP2
SCHEMBL5039087 0.82 GRM5 (0.57) GRM5HPGDKDM4EMAPTUSP2
SCHEMBL4683102 0.81 CYP2C19 (0.49) HPGDKDM4EALDH1A1NPSR1HTT
SCHEMBL4680787 0.80 GRM5 (0.47) GRM5HPGDKDM4EMAPTALDH1A1
SCHEMBL4421873 0.79 GRM5 (0.55) GRM5HPGDKDM4EMAPTUSP2
SCHEMBL4680031 0.78 KDM4E (0.50) GRM5HPGDKDM4EMAPTUSP2
SCHEMBL4684508 0.76 ALDH1A1 (0.42) GRM5HPGDKDM4EMAPTUSP2
SCHEMBL4682517 0.76 LMNA (0.42) GRM5HPGDKDM4EMAPTUSP2
SCHEMBL4684173 0.76 LMNA (0.42) GRM5HPGDKDM4EMAPTUSP2
SCHEMBL4684116 0.75 KDM4E (0.50) GRM5HPGDKDM4EMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004001-A1 Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors MERZ PHARMA GMBH & CO., KGAA (DE) 2006-01-05 US claimed
EP-1943247-A1 TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Merz Pharma GmbH & Co.KGaA (DE) 2008-07-16 EP disclosed
WO-2007023245-A1 TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERZ PHARMA GMBH & CO. KGAA (DE) 2007-03-01 WO disclosed
WO-2007023245-A1 TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERZ PHARMA GMBH & CO. KGAA (DE) 2007-03-01 WO disclosed
US-20060004001-A1 Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors MERZ PHARMA GMBH & CO., KGAA (DE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004001-A1 Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors GRM1, GRM5, GRM2 GRM5 2/4885HPGD 775/4885KDM4E 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.